Odm-208

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of ODM-208, a new drug designed to treat metastatic castration-resistant prostate cancer. This first-in-man study aims to determine the drug’s safety profile, tolerability, and optimal dosage for patients facing this challenging form of cancer.

Related diseases and areas:

• Hormone-refractory prostate…

Odm-212

A groundbreaking clinical trial is underway to investigate the potential of ODM-212, a new drug being tested for patients with advanced solid tumors. This multi-site, open-label study aims to evaluate the safety and effectiveness of ODM-212 in two parts: dose escalation and dose expansion. The trial represents an important step in understanding how this novel treatment may benefit patients with difficult-to-treat solid tumors.

Related diseases and areas:

• Neoplasm malignant
• Neurodevelopmental disorder

Odronextamab

Odronextamab is an experimental drug being studied in clinical trials for various types of B-cell lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma, and other non-Hodgkin lymphomas. These trials aim to assess the safety, tolerability, and effectiveness of odronextamab alone or in combination with other treatments compared to standard therapies. The research focuses on patients with both newly diagnosed and relapsed/refractory disease.

Related diseases and areas:

• Nodal marginal zone B-cell …
• Follicular lymphoma
• B-cell lymphoma
• Marginal zone lymphoma
• Diffuse large B-cell lymphoma
• Splenic marginal zone lymphoma

Ofatumumab

Ofatumumab is a fully human monoclonal antibody that has shown promise in treating several conditions, including chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and other B-cell related disorders. This article explores the use of ofatumumab in various clinical trials, highlighting its potential benefits and applications across different medical conditions.

Related diseases and areas:

• Secondary progressive multi…
• Multiple sclerosis relapse
• Primary progressive multipl…
• Relapsing-remitting multipl…
• Nervous system disorder
• Progressive multiple sclerosis

Ofloxacin

Ofloxacin is an antibiotic medication that has been studied in various clinical trials for different medical conditions. This article explores the use of ofloxacin in clinical research, focusing on its effectiveness, potential side effects, and comparisons with other treatments. We’ll examine trials involving ofloxacin for urinary tract infections, bone and joint infections, diabetic foot ulcers, and other conditions.

Related diseases and areas:

• Spinal cord injury
• Multiple sclerosis
• Pneumonia

Ofloxacin Hydrochloride

Ofloxacin Hydrochloride is an antibiotic medication that has been studied in various clinical trials for different medical conditions. This article explores the use of Ofloxacin Hydrochloride in clinical research, focusing on its effectiveness, potential applications, and comparison with other treatments. We’ll examine trials involving this drug for conditions like bone and joint infections, diabetic foot ulcers, and as a prophylactic measure in certain medical procedures.

Related diseases and areas:

• Bacteraemia
• Haematological infection
• Pneumonia
• Medical device site joint i…
• Appendicitis

Olaparib

Olaparib, also known by its brand name Lynparza, is a promising drug being studied in various clinical trials for the treatment of different types of cancer. This article summarizes key information about ongoing clinical trials investigating the use of olaparib in conditions like ovarian, breast, prostate, and pancreatic cancers. We’ll explore how this PARP inhibitor is being evaluated for its efficacy, safety, and potential to improve outcomes for cancer patients.

Related diseases and areas:

• Hormone-refractory prostate…
• Prostate cancer
• Squamous cell carcinoma of …
• Breast cancer metastatic
• HER2 negative breast cancer
• Small cell lung cancer exte…

Olaptesed Pegol

Olaptesed Pegol, also known as NOX-A12, is an innovative drug being investigated in clinical trials for its potential in treating various types of cancer. This article explores the use of Olaptesed Pegol in clinical trials, focusing on its application in colorectal cancer, pancreatic cancer, and glioblastoma. We’ll discuss how this drug works, its combination with other treatments, and the ongoing research to evaluate its safety and efficacy.

Related diseases and areas:

• Glioblastoma

Oleclumab

Oleclumab is an innovative immunotherapy drug being studied in clinical trials for various types of cancer. This article examines ongoing research investigating oleclumab alone and in combination with other treatments, focusing on its potential benefits, safety profile, and effectiveness in improving outcomes for cancer patients.

Related diseases and areas:

• Non-small cell lung cancer …
• Non-small cell lung cancer …
• Breast cancer recurrent
• Non-small cell lung cancer …
• Breast cancer metastatic
• Non-small cell lung cancer

Olmesartan Medoxomil

Olmesartan Medoxomil, an angiotensin II receptor blocker, has been the subject of numerous clinical trials exploring its efficacy in treating hypertension and other related conditions. This article summarizes key findings from recent studies, highlighting the drug’s potential benefits, safety profile, and applications in various patient populations.

Related diseases and areas:

• Focal segmental glomerulosc…
• Essential hypertension
• Cardiac failure
• Hypertension

Olorofim

Olorofim, also known as F901318, is an investigational antifungal drug currently being studied in clinical trials for the treatment of invasive fungal infections. These trials are evaluating olorofim’s effectiveness, safety, and pharmacokinetics in various patient populations and dosing regimens. The drug shows potential as a novel treatment option, especially for infections resistant to current therapies.

OLVEREMBATINIB

Olverembatinib (also known as HQP1351) is a novel third-generation tyrosine kinase inhibitor (TKI) that shows promise in treating various blood cancers, particularly those with the Philadelphia chromosome. This drug is currently being investigated in multiple clinical trials across different conditions, including chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and other rare blood disorders. Olverembatinib has shown effectiveness against resistant forms of these diseases, including those with the challenging T315I mutation that makes them resistant to earlier-generation TKIs. This article explores the current clinical trials evaluating olverembatinib’s efficacy, safety, and potential combinations with other therapies.

Related diseases and areas:

• Acute lymphocytic leukaemia
• Philadelphia chromosome pos…
• Chronic myeloid leukaemia

Omaveloxolone

Omaveloxolone, also known as RTA 408 or SKYCLARYS, is an investigational drug being studied in clinical trials for various conditions, particularly Friedreich’s Ataxia. This article summarizes key information from multiple clinical trials examining the safety, effectiveness, and pharmacokinetics of omaveloxolone in different patient populations.

Related diseases and areas:

• Friedreich’s ataxia

OMECAMTIV MECARBIL

Omecamtiv mecarbil, also known as CK-1827452, is an investigational medication being studied for its potential benefits in treating heart failure. This cardiac myosin activator works in a unique way by enhancing heart muscle contraction without increasing the heart’s oxygen demand. Clinical trials have examined various formulations of this drug—including intravenous infusions and oral capsules—in patients with heart failure, ischemic cardiomyopathy, and angina. These studies have focused on understanding how the drug affects heart function, exercise capacity, and overall cardiac efficiency while monitoring its safety profile and determining optimal dosing regimens.

Omeprazole

Omeprazole, a widely used proton pump inhibitor, has been the subject of numerous clinical trials to evaluate its efficacy and safety in treating various gastrointestinal conditions. This article summarizes key findings from clinical studies investigating omeprazole’s use in different formulations, dosages, and patient populations. We’ll explore its effects on gastric acid suppression, bioequivalence with other medications, and its role in managing conditions such as eosinophilic esophagitis and post-bariatric surgery care.

Related diseases and areas:

• Gastrooesophageal reflux di…
• Gastrointestinal disorder

Omo-103

OMO-103 is an innovative drug currently being studied in clinical trials for its potential in treating advanced high-grade osteosarcoma and metastatic pancreatic cancer. This article delves into the ongoing research, exploring how this Myc inhibitor is being evaluated for safety, efficacy, and its impact on patients’ quality of life in these challenging cancer types.

Related diseases and areas:

• Osteosarcoma metastatic

Omp10

This article explores the use of OMP10, a component of the innovative cancer vaccine EO4010, in clinical trials for patients with metastatic colorectal cancer. The study aims to evaluate the safety and effectiveness of OMP10 in combination with other cancer treatments, offering new hope for patients who have previously undergone treatment for this advanced form of cancer.

Related diseases and areas:

• Colorectal cancer metastatic

Omp11

The AUDREY study is a global multicenter phase 1/2 clinical trial exploring the potential of EO4010, a novel microbial-derived peptide therapeutic vaccine containing Omp11, in combination with nivolumab and/or bevacizumab for patients with previously treated metastatic colorectal carcinoma. This groundbreaking research aims to evaluate the safety, tolerability, and efficacy of this innovative treatment approach for patients who have limited options after standard therapies.

Related diseases and areas:

• Colorectal cancer metastatic

Omp12

The AUDREY study is a global multicenter phase 1/2 clinical trial investigating the use of EO4010, a novel microbial-derived peptide therapeutic vaccine containing OMP12, in combination with nivolumab and/or bevacizumab for patients with previously treated metastatic colorectal carcinoma. This trial aims to evaluate the safety, tolerability, and potential effectiveness of this innovative combination therapy in patients who have limited treatment options.

Related diseases and areas:

• Colorectal cancer metastatic

Omp64

This article explores the ongoing clinical trials of EO2463, an innovative microbial-derived peptide therapeutic vaccine being studied for the treatment of indolent Non-Hodgkin’s Lymphoma. The trials aim to evaluate the safety, efficacy, and potential combinations of EO2463 with other treatments in patients with Follicular Lymphoma and Marginal Zone Lymphoma.

Related diseases and areas:

• Non-Hodgkin’s lymphoma

Omp65

This article explores the clinical trials of EO2463, an innovative cancer vaccine therapy being studied for the treatment of indolent Non-Hodgkin’s Lymphoma, specifically Follicular Lymphoma and Marginal Zone Lymphoma. The trials aim to evaluate the safety, efficacy, and potential combinations of EO2463 with other treatments in both newly diagnosed and previously treated patients.

Related diseases and areas:

• Non-Hodgkin’s lymphoma

Omp66

This article explores the ongoing clinical trials of EO2463, a groundbreaking cancer vaccine therapy being tested for patients with indolent Non-Hodgkin’s Lymphoma. The study aims to evaluate the safety, efficacy, and potential combinations of EO2463 with other treatments like lenalidomide and rituximab. This innovative approach could offer new hope for patients with Follicular Lymphoma and Marginal Zone Lymphoma.

Related diseases and areas:

• Non-Hodgkin’s lymphoma

Omp72

This article discusses the clinical trials of EO2463, an innovative cancer vaccine therapy being studied for the treatment of indolent Non-Hodgkin’s Lymphoma (NHL). The trials aim to evaluate the safety, efficacy, and optimal dosing of EO2463 when used alone or in combination with other treatments like lenalidomide and rituximab. The study focuses on patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL), two subtypes of indolent NHL.

Related diseases and areas:

• Non-Hodgkin’s lymphoma

Oms906

OMS906 is an investigational drug currently being studied in clinical trials for the treatment of rare blood and kidney disorders. These trials aim to evaluate the safety, efficacy, and potential benefits of OMS906 in patients with conditions such as Paroxysmal Nocturnal Hemoglobinuria (PNH), C3 Glomerulopathy (C3G), and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN). The ongoing research seeks to determine if OMS906 can improve symptoms and quality of life for patients with these challenging diseases.

Related diseases and areas:

• Glomerulonephritis
• Paroxysmal nocturnal haemog…

OMTX705

OMTX705 is an innovative antibody-drug conjugate currently being investigated in clinical trials for patients with advanced solid tumors. This open-label, multicenter Phase 1 study examines OMTX705 both as a standalone treatment and in combination with pembrolizumab (Keytruda) for patients who have exhausted standard treatment options. The trial aims to establish safe dosing levels, evaluate side effects, and gather preliminary data on the drug’s effectiveness against various advanced cancers. This article summarizes key information about this ongoing research to help patients understand this potential new treatment approach.

Related diseases and areas:

• Colorectal cancer metastatic

Omx-0407

A new drug called OMX-0407 is currently being studied in clinical trials for patients with solid tumors that cannot be removed surgically. This article will provide an overview of the ongoing research, including the study’s purpose, design, and expected outcomes. The information presented here is based on a Phase I/Ib clinical trial aimed at evaluating the safety, effectiveness, and proper dosing of OMX-0407 in patients with previously treated solid tumors.

Related diseases and areas:

• Neoplasm

Onasemnogene Abeparvovec

Onasemnogene Abeparvovec, also known as Zolgensma, is a groundbreaking gene therapy drug being studied in clinical trials for the treatment of Spinal Muscular Atrophy (SMA). These trials aim to assess the long-term safety and effectiveness of the drug in patients who have received it through intravenous (IV) or intrathecal (IT) administration. The studies focus on monitoring adverse events, developmental milestones, motor function, and overall quality of life for patients with SMA over extended periods, ranging from 5 to 15 years.

Related diseases and areas:

• Spinal muscular atrophy

Onfekafusp Alfa

Onfekafusp alfa, also known as L19TNF, is an innovative tumor-targeting human antibody-cytokine fusion protein being studied in clinical trials for the treatment of glioblastoma and soft tissue sarcoma. This article explores the ongoing research into this promising drug, including its potential efficacy, safety profile, and combination therapies with other anticancer agents.

Related diseases and areas:

• Squamous cell carcinoma of …
• Skin cancer
• Superficial spreading melan…
• Malignant melanoma stage III
• Soft tissue sarcoma
• Basal cell carcinoma

Onopordum Acanthium, Flos Rec., Ethanol. Digestio 1:3,1 Cum 1 % Hyoscyamus Ø

This article discusses a clinical trial investigating the use of Cardiodoron® Dilution, containing Onopordum Acanthium and Primula Veris extracts, for patients with functional cardiovascular disorders (FCD). The study aims to evaluate the efficacy and safety of this anthroposophic medicinal product compared to a placebo in managing FCD symptoms and improving quality of life.

Related diseases and areas:

• Cardiovascular somatic symp…

Opelconazole

A clinical trial is underway to evaluate the safety and effectiveness of Opelconazole, a new drug designed to prevent fungal infections in the lungs of patients who have received lung transplants. This study, known as the OPERA-S Study, aims to compare Opelconazole with standard care methods in protecting vulnerable transplant recipients from a condition called pulmonary aspergillosis.

Related diseases and areas:

• Bronchopulmonary aspergillosis

Opevesostat

Opevesostat (MK-5684) is an experimental drug being studied in clinical trials for the treatment of metastatic castration-resistant prostate cancer (mCRPC). These trials aim to evaluate the safety, efficacy, and pharmacokinetics of opevesostat alone and in combination with other therapies in patients who have progressed on previous treatments. The studies span different phases and compare opevesostat to existing therapies like abiraterone and enzalutamide.

Related diseases and areas:

• Hormone-refractory prostate…

Opevesostat Tosilate

Opevesostat Tosilate is an investigational drug currently being studied in clinical trials for the treatment of advanced prostate cancer, specifically metastatic castration-resistant prostate cancer (mCRPC). These trials aim to evaluate the safety, efficacy, and potential benefits of Opevesostat Tosilate compared to existing treatments for patients who have progressed on or after prior hormonal therapies and chemotherapy. The studies are exploring various combinations and treatment strategies to improve outcomes for patients with this challenging form of prostate cancer.

Related diseases and areas:

• Prostate cancer
• Hormone-refractory prostate…
• Prostate cancer metastatic
• Ovarian cancer
• Endometrial cancer
• Breast cancer

Opium, Standardized Powdered

This article discusses a clinical trial investigating the use of a medication containing opium, standardized powdered, along with colchicine, for patients with moderate chronic kidney disease. The study aims to evaluate the effectiveness of this treatment in preventing cardiovascular events and slowing the progression of kidney disease. We’ll explore the trial’s objectives, eligibility criteria, and potential outcomes for patients with this condition.

Related diseases and areas:

• Nephropathy
• Acute myocardial infarction
• Arteriosclerosis

Oregovomab

Oregovomab is an experimental drug being studied in clinical trials for the treatment of ovarian cancer. This article explores the use of Oregovomab in various clinical trials, its potential benefits, and its role in immunotherapy for ovarian cancer patients. We’ll discuss how Oregovomab works, its combination with other treatments, and the ongoing research to determine its effectiveness in improving patient outcomes.

Related diseases and areas:

• Ovarian cancer
• Malignant peritoneal neoplasm
• Fallopian tube cancer

ORG-129

A groundbreaking clinical trial is currently underway to evaluate the investigational drug ORG-129 in healthy volunteers. This “First in Human” study aims to assess how safe and well-tolerated ORG-129 is when taken orally, while also examining how the drug moves through the body. The research includes both single and multiple dose administration to understand the drug’s behavior and effects in the human body. This initial testing in healthy individuals represents a crucial first step in the drug development process, providing valuable information that may guide future studies of ORG-129 in patient populations.

Related diseases and areas:

• Crohn’s disease

Oric-114

ORIC-114 is an innovative drug currently being studied in clinical trials for its potential in treating advanced solid tumors and non-small cell lung cancer (NSCLC) with specific genetic alterations. This brain-penetrant, selective, orally bioavailable, irreversible small molecule inhibitor targets EGFR and HER2 mutations, offering hope for patients with limited treatment options, including those with brain metastases. The ongoing trials aim to establish the drug’s safety, effectiveness, and optimal dosing, both as a single agent and in combination with other treatments.

Related diseases and areas:

• Neoplasm

Orismilast

Orismilast, a next-generation phosphodiesterase-4 (PDE4) inhibitor, is currently being studied in clinical trials for various inflammatory skin conditions. This article explores the ongoing research on Orismilast’s potential effectiveness and safety in treating hidradenitis suppurativa, psoriasis, and atopic dermatitis. We’ll delve into the key aspects of these trials and what they mean for patients suffering from these challenging skin disorders.

Related diseases and areas:

• Colitis ulcerative
• Obesity

Oritavancin

Oritavancin is an antibiotic being studied in clinical trials for the treatment of various bacterial infections, particularly those caused by gram-positive bacteria. This article summarizes key findings from recent clinical trials investigating the safety, efficacy, and potential applications of oritavancin in different patient populations and infection types.

Related diseases and areas:

• Skin bacterial infection
• Skin disorder

Orlistat

This article examines the use of orlistat, a medication used for weight loss, in various clinical trials. Orlistat works by inhibiting fat absorption in the intestines. The trials discussed here investigate orlistat’s effectiveness for weight loss maintenance, its impact on uric acid levels, its potential use in rare metabolic disorders, and its safety profile. We’ll explore how orlistat compares to other formulations and its effects on different patient populations.

Related diseases and areas:

• Obesity
• Liver disorder

ORX750

ORX750 is an investigational drug currently being studied in clinical trials for people with narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH). These rare conditions cause excessive daytime sleepiness that can significantly impact daily activities. ORX750 is designed to mimic the action of orexin, a protein in the brain that helps people stay awake during the day. The current clinical trials aim to evaluate the safety, tolerability, and effectiveness of ORX750 in reducing symptoms associated with these sleep disorders. Let’s explore what these trials reveal about this promising treatment option.

Related diseases and areas:

• Narcolepsy
• Hypersomnia

Oseltamivir

This article summarizes key findings from clinical trials investigating the use of oseltamivir (Tamiflu) for treating influenza in various patient populations. The trials examined aspects such as dosing, safety, pharmacokinetics, and efficacy in groups including children, obese adults, and immunocompromised patients.

Related diseases and areas:

• H1N1 influenza
• Respiratory tract infection
• Influenza
• Pneumonia

Osilodrostat

Osilodrostat is an investigational drug being studied as a potential treatment for Cushing’s syndrome, a rare hormonal disorder caused by excessive cortisol production. Clinical trials are evaluating osilodrostat’s safety and efficacy in reducing cortisol levels and improving symptoms in patients with various forms of Cushing’s syndrome. This article summarizes key findings from recent clinical trials of osilodrostat.

Related diseases and areas:

• Pituitary-dependent Cushing…

OSIMERTINIB MESYLATE

Osimertinib mesylate is a targeted cancer medicine taken by mouth that is being studied in several clinical trials, mainly for non-small cell lung cancer (NSCLC) with specific EGFR gene mutations. These trials look at how well it works in different situations (first treatment, after surgery, and after resistance develops) and also test it in combinations with other anti-cancer drugs. This article explains what these studies are testing, what outcomes they measure, and what participation may involve.

Related diseases and areas:

• Neoplasm malignant

Osteodex

Osteodex, a novel poly-bisphosphonate drug containing dextran, alendronate, and guanidine, is being studied in clinical trials for its potential in treating metastatic castration-resistant prostate cancer (CRPC) and multiple myeloma. These trials aim to evaluate the safety, efficacy, and optimal dosing of Osteodex in patients with these challenging conditions. The studies focus on various aspects, including bone metabolism markers, overall survival, and quality of life improvements.

Related diseases and areas:

• Plasma cell myeloma

Oteracil

Oteracil, a component of several combination cancer drugs, is currently being studied in various clinical trials for its potential in treating different types of cancer. This article explores the ongoing research on Oteracil’s efficacy and safety in combination therapies for colorectal, gastric, esophageal, pancreatic, breast, and cervical cancers. We’ll examine the latest findings from these trials and what they mean for patients and the future of cancer treatment.

Related diseases and areas:

• Pancreatic carcinoma metast…
• Rectal cancer recurrent
• Breast cancer